Albeit CML patients with the T315I-BCR-ABL mutation respond well to ponatinib38, an increased risk of thromboembolism with ponatinib seemed not inevitable26. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.